Skip to main content
Back to feed
MarketsSingle-sourceLow
2.1

Xintela reports reduced Q2 2026 pre-tax loss of 9.8 million SEK

Swedish biotech firm Xintela narrowed its pre-tax loss to 9.8 million SEK in Q2 2026, compared to 12.1 million SEK in the same period last year. The report reflects ongoing operational costs for its stem cell and cancer therapy development programs.

Dagens Industri1 day agoSECredibility 27%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#biotech#earnings#xintela#sweden

Locations

Lund

Entities

country
Source

Related signals

8 found